Russell Investments Group
AARD

Russell Investments Group’s Aardvark Therapeutics AARD Stock Holding History

Russell Investments Group’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.77K Hold
469
– – ﹤0.01% 4008
2025
Q4 		$6.16K Hold
469
– – ﹤0.01% 3877
2025
Q3 		$6.23K Buy
+469
New +$5.29K ﹤0.01% 3862

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Russell Investments Group's AARD Position: Q1 2026 in Review

Russell Investments Group held its Aardvark Therapeutics (AARD) position steady in Q1 2026 at 469 shares worth $1.77K. The position accounts for ﹤0.01% of the portfolio, ranked #4008.

Russell Investments Group first reported a position in AARD in Q3 2025 and has held it in 3 quarters since. The position peaked at $6.23K in Q3 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Russell Investments Group held 469 shares of Aardvark Therapeutics worth $1.77K as of Q1 2026.
  • Russell Investments Group left its Aardvark Therapeutics share count unchanged in Q1 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #4008 holding.
  • Russell Investments Group first reported a position in Aardvark Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Russell Investments Group's Aardvark Therapeutics position peaked at $6.23K in Q3 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.